Mathew S Maurer1, Donna R Grogan2, Daniel P Judge2, Rajiv Mundayat2, Jeff Packman2, Ilise Lombardo2, Arshed A Quyyumi2, Janske Aarts2, Rodney H Falk2. 1. From the Clinical Cardiovascular Research Laboratory for the Elderly (CCRLE), Columbia University Medical Center, New York Presbyterian Hospital (M.S.M.); Drug Development Department, FoldRx Pharmaceuticals/Pfizer Inc, Cambridge, MA (D.R.G., J.P.); Department of Medicine/Cardiology, Center for Inherited Heart Disease, Johns Hopkins University, Baltimore, MD (D.P.J.); Global Medicines Development (GMD) (J.A., I.L.) and Global Innovative Pharma - Statistics (R.M.), Pfizer Inc, New York, NY; Department of Medicine, Emory University School of Medicine, Atlanta, GA (A.A.Q.); and Department of Cardiology, Harvard Vanguard Medical Associates, Harvard Medical School, Boston, MA (R.H.F.). msm10@columbia.edu. 2. From the Clinical Cardiovascular Research Laboratory for the Elderly (CCRLE), Columbia University Medical Center, New York Presbyterian Hospital (M.S.M.); Drug Development Department, FoldRx Pharmaceuticals/Pfizer Inc, Cambridge, MA (D.R.G., J.P.); Department of Medicine/Cardiology, Center for Inherited Heart Disease, Johns Hopkins University, Baltimore, MD (D.P.J.); Global Medicines Development (GMD) (J.A., I.L.) and Global Innovative Pharma - Statistics (R.M.), Pfizer Inc, New York, NY; Department of Medicine, Emory University School of Medicine, Atlanta, GA (A.A.Q.); and Department of Cardiology, Harvard Vanguard Medical Associates, Harvard Medical School, Boston, MA (R.H.F.).
Abstract
BACKGROUND: Transthyretin (TTR) amyloidosis is a progressive systemic disorder caused by misfolded TTR monomers that cumulatively deposit in the heart and systemically as amyloid. METHODS AND RESULTS: This phase 2 open-label trial evaluated the stabilization of TTR tetramers using 20 mg of tafamidis daily at week 6 (primary end point), month 6, and month 12, as well as safety of tafamidis treatment and efficacy with respect to progression of TTR amyloid cardiomyopathy. Thirty-one wild-type patients (median age, 76.7 years; 93.5% men) with a median disease duration of 55.6 months and mild to moderate heart failure (96.8%; New York Heart Association, classes I-II) were enrolled. Thirty of 31 patients (96.8%) achieved TTR stabilization after 6 weeks and 25 of 28 patients (89.3%) after 12 months. After 12 months of treatment, 3 patients discontinued prematurely, 2 patients died, 7 patients were hospitalized because of cardiovascular events, 20 of 28 patients demonstrated preserved New York Heart Association classification status, but 15 of 31 (48.4%) patients had clinical progression (eg, admission for cardiac failure, atrial fibrillation, and syncope). N-terminal prohormone brain natriuretic peptide levels did not increase significantly over time, troponin I and troponin T increased moderately, and no consistent clinically relevant changes were seen in echocardiographic cardiac assessments. Tafamidis treatment was generally well tolerated although 7 of 31 patients had bouts of diarrhea. CONCLUSIONS: Tafamidis treatment effectively achieved and maintained TTR stabilization and was well tolerated. The absence of significant changes in most biochemical and echocardiographic parameters suggests that further evaluation of tafamidis in TTR amyloid cardiomyopathy is warranted. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT00694161.
BACKGROUND:Transthyretin (TTR) amyloidosis is a progressive systemic disorder caused by misfolded TTR monomers that cumulatively deposit in the heart and systemically as amyloid. METHODS AND RESULTS: This phase 2 open-label trial evaluated the stabilization of TTR tetramers using 20 mg of tafamidis daily at week 6 (primary end point), month 6, and month 12, as well as safety of tafamidis treatment and efficacy with respect to progression of TTRamyloid cardiomyopathy. Thirty-one wild-type patients (median age, 76.7 years; 93.5% men) with a median disease duration of 55.6 months and mild to moderate heart failure (96.8%; New York Heart Association, classes I-II) were enrolled. Thirty of 31 patients (96.8%) achieved TTR stabilization after 6 weeks and 25 of 28 patients (89.3%) after 12 months. After 12 months of treatment, 3 patients discontinued prematurely, 2 patientsdied, 7 patients were hospitalized because of cardiovascular events, 20 of 28 patients demonstrated preserved New York Heart Association classification status, but 15 of 31 (48.4%) patients had clinical progression (eg, admission for cardiac failure, atrial fibrillation, and syncope). N-terminal prohormone brain natriuretic peptide levels did not increase significantly over time, troponin I and troponin T increased moderately, and no consistent clinically relevant changes were seen in echocardiographic cardiac assessments. Tafamidis treatment was generally well tolerated although 7 of 31 patients had bouts of diarrhea. CONCLUSIONS:Tafamidis treatment effectively achieved and maintained TTR stabilization and was well tolerated. The absence of significant changes in most biochemical and echocardiographic parameters suggests that further evaluation of tafamidis in TTRamyloid cardiomyopathy is warranted. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT00694161.
Authors: Marios Arvanitis; Clarissa M Koch; Gloria G Chan; Celia Torres-Arancivia; Michael P LaValley; Daniel R Jacobson; John L Berk; Lawreen H Connors; Frederick L Ruberg Journal: JAMA Cardiol Date: 2017-03-01 Impact factor: 14.676
Authors: Balaji Tamarappoo; Yuka Otaki; Osamu Manabe; Mark Hyun; Stephanie Cantu; Yoav Arnson; Heidi Gransar; Sean W Hayes; John D Friedman; Louise Thomson; Piotr Slomka; Damini Dey; Robert Vescio; Jignesh Patel; Daniel S Berman Journal: J Nucl Cardiol Date: 2019-06-06 Impact factor: 5.952
Authors: Frederick L Ruberg; Martha Grogan; Mazen Hanna; Jeffery W Kelly; Mathew S Maurer Journal: J Am Coll Cardiol Date: 2019-06-11 Impact factor: 24.094
Authors: M Ankarcrona; B Winblad; C Monteiro; C Fearns; E T Powers; J Johansson; G T Westermark; J Presto; B-G Ericzon; J W Kelly Journal: J Intern Med Date: 2016-05-10 Impact factor: 8.989
Authors: Alexander Marco Kollikowski; Florian Kahles; Svetlana Kintsler; Sandra Hamada; Sebastian Reith; Ruth Knüchel; Christoph Röcken; Felix Manuel Mottaghy; Nikolaus Marx; Mathias Burgmaier Journal: Intractable Rare Dis Res Date: 2017-11
Authors: Joseph D Schonhoft; Cecilia Monteiro; Lars Plate; Yvonne S Eisele; John M Kelly; Daniel Boland; Christopher G Parker; Benjamin F Cravatt; Sergio Teruya; Stephen Helmke; Mathew Maurer; John Berk; Yoshiki Sekijima; Marta Novais; Teresa Coelho; Evan T Powers; Jeffery W Kelly Journal: Sci Transl Med Date: 2017-09-13 Impact factor: 17.956